Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 15Active not recruiting 5Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × navitoclax × Clear all
NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

AbbVie

Phase 1 Terminated
1 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡